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Abstract: Association between HLA-DR4 and rheumatoid arthritis (RA) has been known for 4 decades, and amino acid 
sites within HLA-DRB1 (11/13, 71, 74) are highly associated with RA. HLA is not useful for diagnosis or prognosis, 
but it may help predict severe and erosive disease. Since 90% of patients with ankylosing spondylitis (AS) and 50-70% 
of other spondyloarthritis (SpA) patients are HLA-B*27 positive, HLA is a stronghold of diagnostic algorithms. Genetic 
predisposition to juvenile idiopathic arthritis (JIA) is mainly due to HLA class II, and to a lesser extent to HLA class I. 
Although HLA plays a role in rheumatic disorders, its clinical relevance is not homogeneous. When classical 
biomarkers are lacking or in complex cases, HLA typing may provide support for the management of patients. 
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Over 100 diseases are associated with classical HLA 
class I and II genes.
1
 When addressing the relevance of 
HLA and disease association studies, we should not 
forget that ethnic differences, the definition of the 
patient group, the advancements of typing techniques, 
statistical methods and, finally, linkage disequilibrium 
might all influence the application of research results to 
clinical practice. 
HLA and disease association studies can be divided in 
two distinct eras, the first pioneering phase spanning 
from the late ‘70s to the beginning of the 21st century, 
and the second period of the past 20 years, which we 
might call the genomic era.  
The main findings and knowledge obtained in the 
pioneering phase of HLA and disease association 
studies are described in Thorsby and Lie’s review 
published in 2005.
2
 The authors discuss the 
contribution of HLA genes to specific autoimmune 
diseases and, for some of these, an indication of 
Relative Risk (RR) is provided. The RR is of 
significance for clinical application since it indicates 
the likelihood that the disease will occur among 
individuals positive for the predisposing allele, 
compared with individuals negative for the same allele. 
Thorsby and Lie clarify some mechanisms involved in 
autoimmune disease pathogenesis and suggest that, for 
those diseases which develop gradually over a long 
period of time, for example type 1 diabetes, knowing 
the susceptibility genes may allow early diagnosis and 
thus improve the management of the affected patients. 
The Human Genome Project
3
 paved the way for the 
newer studies published in the first twenty years of the 
new century. In 2007, the Wellcome Trust Case 
Control Consortium published a genome-wide 
association study (GWAS) of 14,000 cases of seven 
common diseases, three of which have variable 
autoimmune pathogenetic components (Crohn’s 
disease, rheumatoid arthritis (RA) and type 1 
diabetes).
4
 It is interesting to note that, for RA and type 
1 diabetes, the vast majority of the independent 
association signals could be mapped to chromosome 6 
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and, more specifically, to the Major Histocompatibility 
Complex (MHC). 
Information obtained through genomic studies shed 
more light on HLA association and autoimmune 
diseases than the previous approaches. Trowsdale and 
Knight
5
 describe the impact of the new technologies on 
these studies and, in particular, the authors comment on 
the importance of GWAS in revealing new HLA 
specificities and underline the multifactorial nature of 
autoimmune conditions. Moreover, they comment on 
the new imputation approach to HLA typing, a method 
first described by Leslie and coworkers in 2008.
6
 As an 
alternative to direct HLA sequencing, imputation 
allows the screening of a large number of samples with 
fewer costs, guaranteeing robust statistical power; 
imputation is a means of addressing and partly 
overcoming the problems related to linkage 
disequilibrium. One such example is the pivotal study 
by Raychaudhuri and colleagues
7
, which analyzed 
more than 5,000 RA patients comparing them with 
15,000 controls. 
More recently, studies aimed at improving the insight 
into MHC susceptibility for autoimmune diseases have 
been published.
8
 Specifically, fine-mapping approaches 
have generally confirmed the previous main results and 
have identified new alleles or single amino acids 
associated with diseases. To further study the 
immunogenetics of autoimmune disease, a specific 
chip, called Immunochip (Illumina, Inc., CA), was 
created about 10 years ago and widely used to study 
several conditions, for example Crohn’s disease, type 1 
diabetes, RA, ankylosing spondylitis (AS).
9
 It contains 
a concentrated panel of SNPs from the MHC and is 
cheaper and faster than ordinary GWAS. 
It is important to point out that these are population 
studies conducted for research, which help in revealing 
molecular pathways of disease pathogenesis, but are 
not intended for clinical use. 
Although it is difficult to estimate the number of 
clinical HLA disease association studies annually 
performed in Europe, a study carried out by EFI 
(European Federation for Immunogenetics)
10
 indicated 
that, in 2012, EFI accredited laboratories performed 
approximately 225,000 HLA and disease association 
studies. 
In 2010, a study group established by the Italian 
Association of Transplantation Biology and 
Immunogenetics (AIBT) wrote practical 
recommendations for HLA association studies of 
relevance for clinical practice.
11
 On a more local basis, 
of the 2700 clinical requests for HLA and disease 
association studies processed by our laboratory 
between 2009 and 2014, 50% regarded 
rheumatological diseases
12
, and it is of note that this 
proportion is increasing. 
The aim of this paper is to review the role of HLA in 
some rheumatic diseases, namely rheumatoid arthritis 
(RA), spondyloarthritis (SpA), both axial (axSpA) and 
peripheral, including psoriatic arthritis (PsA), and 
Juvenile Idiopathic Arthritis (JIA), and to give some 
practical indications on the role of HLA typing in the 




Rheumatoid arthritis (RA) 
RA is the most common inflammatory arthritis which 
primarily targets synovial joints resulting in significant 
pain, functional limitations and mortality.
13
 Early 
recognition of this disease, along with its extra-articular 
manifestations, can lead to faster time to treatment and 
better health outcomes, in addition to preserved joint 
functionality. The most relevant biomarkers used in 
clinical management of RA are Rheumatoid Factor 
(RF) and antibodies to citrullinated peptides (ACPA)
14
; 
however, neither of the tests is sufficiently specific to 
establish the diagnosis of RA, and prognosis varies 
widely with seropositive and seronegative patients. 
HLA-DR4 has been known to be associated with 
European RA patients for more than 4 decades
15
, and it 
is widely accepted that the HLA-DRB1 gene is the 
major genetic susceptibility locus for RA. The HLA 
alleles DRB1*04:01,*04:04,*04:05 and *04:08 mostly 
explain the originally observed serological association. 
Moreover, some HLA-DRB1*01 and DRB1*10 alleles 
have also been found to be associated with RA in 
patients who are negative for DRB1*04. In the late 
‘80s, it was found that the associated alleles shared a 
region of highly similar amino acid (a.a.) sequence, 
leading to speculate that this portion of the HLA-DRB1 
molecule (a.a. 70 to 74), also called shared epitope 
(SE), controls susceptibility to disease.
16
  
In non-European populations with a low frequency of 
HLA-DRB1*04, the associated alleles still contain the 
SE. Table 1 shows the relevance of ethnicity on HLA 
association in RA. 
As reported in the introductory section, a fine-mapping 
study on approximately 5,000 RA seropositive patients 
and 15,000 controls, conducted by Raychaudhuri and 
co-workers
7
, showed that a small number of amino acid 
(a.a.) sites within the HLA-DRB1 protein (positions 
11/13 which are tightly linked, 71 and 74) and single 
a.a. polymorphisms in HLA-B (position 9) and HLA-
DPB1 (position 9), all located in the peptide binding 
grove, almost completely explain the MHC association 
to RA risk. Individuals of European origin can be 
classified into 16 different risk categories solely based 
on their two field HLA-DRB1 type or on the a.a. 
carried at positions 11/13, 71, and 74 of HLA-DRB1.
17
 
The highest risk categories correspond to SE-positive 
individuals, while the lower risk categories are defined 
by protective HLA alleles (for example, HLA-
DRB1*13:01). The importance of HLA-DRB1*13:01 
as a protective allele in the European population was 
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Table 1. HLA and Rheumatoid Arthritis (RA) in different ethnic populations 
 
SEROPOSITIVE RA SERONEGATIVE RA 
Associated HLA alleles 
Caucasians: 
     HLA-DRB1*04:01 in 50-60% of pts RR of 5 – 11 
     HLA-DRB1*04:04 in 27-37% of pts RR of 5 – 14 
     HLA-DRB1*10:01 in 1.5% of pts RR of 2.3 
     HLA-DRB1*01:01 in 13-27% of pts RR of 1 to 2 
     HLA-DRB1*04:08 
Japanese: 
     HLA-DRB1*04:05 
Chinese: 
     HLA-DRB1*04:04, *04:05 
Yakima, Tlingit, Pima Native-American: 
     HLA-DRB1*14:02 
Spanish, Basque, Israeli Jews: 
     HLA-DRB1*01, *10 
HLA-DRB1*03 
HLA-B*08 




Studies which have addressed the role of HLA in 
seronegative RA
19
 demonstrate associations with HLA-
DRB1*03 and HLA-B*08, suggesting that 
seronegative RA is genetically distinct from the 
seropositive disease, and probably has diverse 
autoantigens contributing to pathogenesis. 
The role of genetic and environmental factors on the 
pathogenesis of RA is illustrated in McInnes and 
Schett’s excellent review published in 2011.
13
 
Although the association between HLA and RA is 
widely accepted, according to some authors, HLA 
would only contribute approximately 50% of the global 
genetic risk. Okada and co-authors recently published a 
paper
20
 which lists the known genes associated to RA, 
which amount to about 100. Some of the most relevant 
non-HLA genes associated with the disease are 
PTPN22, CTLA4, TRAF1 and STAT4.  
In the last 10 years, approximately 900 studies have 
been published on HLA and RA (data obtained from 
PubMed, accessed on 29 January 2020). This testifies 
to the interest in the role of immunogenetics in this 
specific rheumatologic condition. However, from a 
practical point of view, most clinicians do not use HLA 





Contrary to other autoimmune diseases, such as AS, the 
alleles strongly associated to RA are common in the 
normal population. A study, published in 1992, 
calculated that individuals carrying HLA-DRB1*04:01, 




In 2013, Balandraud and co-workers
22
 published a 
paper on a patient population of 857 individuals 
affected by ACPA-positive RA and 2178 controls from 
South Eastern France. The authors demonstrated that 
the risk of developing the disease was correlated with 
both HLA-DRB1 alleles carried by patients. Two tables 
are presented in the study: the first reports the Odds 
Ratio (OR) of single alleles or allele groups, whereas 
the second illustrates the risk associated with the 
genotypes. The single allele bearing the greatest risk is 
HLA-DRB1*04:08, with an OR of 10.22. On the other 
hand, the genotype with the highest OR (28.2) is HLA-
DRB1*04:01,*10. 
Although the role of HLA-DRB1 in RA is well-
established, the availability of non-expensive 
serological biomarkers, together with clinical and 
radiological evaluation, does not recommend HLA 
typing for diagnosis at present. 
 
 
Prognosis, severity and response to treatment  
The presence of ACPA at disease onset allows for the 
identification of patients at greater risk of severe 
erosive disease and radiological progression
23, 24
, 
independently of RF positivity.
24
 Patients with high 
titre ACPA should be carefully monitored. Generally, 
these antibodies are present in patients bearing the RA-
associated amino acids at positions 11/13, 71 and 74 of 
HLA-DRB1
7
, therefore HLA typing for prognosis 
cannot be recommended.  
As far as severity is concerned, the most significant 
genetic marker of disease severity is valine at position 
11 of HLA-DRB1, as illustrated by Viatte and 
Barton.
17
 Valine at position 11 is independent from SE 
and, according to the authors, it is associated with 
radiological severity, mortality and treatment response. 
However, the authors believe more data is necessary to 
confirm these findings before recommending HLA 






SpA are a family of rheumatic disorders which share 
some clinical features: inflammation of axial joints 
(especially the sacroiliac joints), asymmetric 
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oligoarthritis (especially of the lower extremities), 
dactylitis (sausage digits), enthesitis (inflammation at 
sites of ligamentous or tendon attachment to bone). 
SpA may also display some additional clinical signs 
such as skin and genital lesions, eye and bowel 
inflammation, an association with preceding or 
ongoing infectious disorders, a positive family history, 
elevated acute phase reactants and, most importantly, a 
strong association with HLA-B*27.
26
  
The SpA family may be classified according to the 
distribution of joint involvement as being 
predominantly axial (axSpA) or peripheral (peripheral 
SpA): 
1) Axial SpA 
 Ankylosing spondylitis (AS) 
 Nonradiographic axial SpA (nr-axSpA) 
2) Peripheral SpA 
 SpA associated with psoriasis or psoriatic 
arthritis (PsA) 
 SpA associated with Crohn disease and 
ulcerative colitis  
 Reactive arthritis  
 Juvenile onset SpA  
Categories do not necessarily represent discrete 
entities, and the clinical, laboratory and imaging 
findings can overlap. Table 2 illustrates the main HLA 
associations with the different subsets of SpA. The 
present review will mainly address AS, as a 




HLA and Ankylosing Spondylitis (AS) 
AS is a potentially disabling SpA with a predominant 
involvement of the spine and/or sacroiliac joints.
27
 
Prevalence of AS ranges from 0.12 to 1.8% in 
Europeans and is a function of the distribution of HLA-
B27 in the population.
28
 In Asia, prevalence is 0.17% 
whereas, in Africa, it is 0.07%.
29
 
The association between HLA-B27 and AS is very 
strong and has been known since 1973.
30
 HLA-B27 is 
present in 90-95% of AS patients in the USA, Europe 
and China. However, in the general population, only 
5% of individuals carrying HLA-B27 will develop AS 
or another form of SpA. The contribution of HLA to 
AS heritability is about 23%. Therefore, even though 
HLA-B27 is necessary for the development of AS, 
apparently it is not sufficient. The RR is greater than 




There are more than 300 HLA-B27 alleles 
(IMGT/HLA database, Release 3.39.0, access date: 25 
February 2020), not all of which are similarly 
associated with SpA and AS. The differences between 
alleles may determine the peptide repertoire, the 
molecular structure and the biogenesis, all factors 
which can influence the antigen presentation and the 
immune response. HLA-B*27:05, the ancestral HLA-
B27 allele from which B*27:02, *27:04 and *27:07 
derive, is strongly associated with AS in Europeans. 
Conversely, HLA-B*27:04 is more frequently 
associated with AS (and more generally with SpA) in 
Chinese and Japanese individuals. It is interesting to 
note that HLA-B*27:06 and *27:09 are not associated 
with either axial or peripheral SpA.
31
  
In addition to HLA-B27, other HLA-B alleles such as 
*13:02, *40:01, *40:02, *47:01 and *51:01 seem to 
show some degree of association with AS, as 




The role of HLA-B27 in the pathogenesis of AS is still 
not clearly understood. As discussed by Bowness in his 
2015 review
33
, at the moment there are two hypotheses. 
The first is the classical binding of antigenic peptides 
to HLA-B27 and their presentation to cytotoxic T cells,  
 
 
Table 2. HLA and Spondyloarthritis (SpA) 
HLA 


















Only  5% of  HLA-
B27+ subjects 
develops AS  
90-95% of patients are  + 
 


















Among            
in-patients with 
more severe 
cases, 60-80% of 
patients + 










   
Legend: IBD - Inflammatory Bowel Disease 
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arthritogenic or self-antigens might be responsible for 
the disease. The second theory regards the misfolding 
of the HLA-B27 molecule, which leads to its 
accumulation in the endoplasmic reticulum, stress and 
autophagy which can induce the production of 
inflammatory cytokines such as Il-23. 
More recently, the role of the gut microbiome and the 
damage to intestinal mucosal barriers in the 
pathogenesis of SpA has been addressed.
34-36
 
For a more detailed description of the pathogenesis of 







HLA and Psoriatic Arthritis (PsA) 
Approximately 30% of patients affected by psoriasis 
will develop psoriatic arthritis at some stage of their 
disease; in the USA, the prevalence is estimated as 
ranging from 0.06 to 0.25%, although figures could be 
higher due to under-reporting.
39
 Even though HLA-
C*06:02 is strongly associated with cutaneous 
psoriasis
40
 and appears to be relevant as a marker of 
response to treatment
41
, its correlation with psoriatic 
arthritis is less significant.
42
 Indeed, HLA-B alleles 
B*08:01, B*39:01 and B*38:01, in addition to 
B*27:05, are more commonly associated with PsA.
43
 
On the other hand, it has been shown that the HLA-B 
alleles B*44:02, B*44:03 and B*40:01 are protective 
for the development of PsA.
43
 Pathogenesis of PsA, 
including the role of non-HLA genes, is thoroughly 






Among the most relevant authors who have studied the 
clinical utility of HLA-B27, Lim, Sengupta and 
Gaffrey, in their review published in 2017
4
, give a 
detailed account of the possible role of HLA-B27 
typing on risk assessment, screening, diagnosis, 
treatment and prognosis. 
The first aspect which must be highlighted is that an 
early diagnosis of axial and peripheral SpA is of 
paramount importance for the clinical outcome. 
HLA is now accepted as part of the diagnostic 
algorithm of SpA, together with the clinical evaluation 
of the rheumatologist or the general practitioner. It is 
important to bear in mind that the presence of HLA-
B27 alone is not diagnostic for axSpA, and the absence 
of HLA-B27 cannot exclude axSpA in European 
individuals since: 
- 85-95% of AS patients and 75-85% of nr-axSpA 
are HLA-B27-positive; 
- HLA-B27 is present in about 8% of the general 
population; 
- only 5% of HLA-B27 subjects will develop AS. 
There are different approaches to the role of HLA-B27 
typing in the diagnostic algorithm of SpA. Among the 
most accepted algorithms, is the one published in 2013 
by van den Berg and co-workers
46
, and validated by the 
Assessment of Spondyloarthiritis International Society 
cohort. This protocol recommends HLA-B27 for 
individuals with chronic back pain (> 3 months, < 45 
years of age onset) and negative radiographic studies 
with less than 4 SpA clinical features, as illustrated by 
Figure 1. Some authors suggest using HLA-B27 for 
screening of patients with chronic low back pain or 
inflammatory back pain (IBP), in whom axSpA is 
suspected: 
- in chronic back pain patients, the probability of 
axSpA is 5% in HLA-B27-negative individuals and 
30% in HLA-B27-positive subjects; 
- in IBP patients, probability of axSpA is 14% in 







Figure 1. Diagnostic algorithm of SpA (modified from van den Berg et al37) 
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As far as the peripheral (non-axial) SpAs are 
concerned, there are no pathognomonic laboratory 
tests. As shown in Table II, HLA-B27 is present in 
approximately 50% of reactive arthritis and peripheral 
SpA without comorbidities. The frequency of HLA-
B27 decreases in psoriatic arthritis and SpA associated 
with inflammatory bowel disease (IBD). Similarly to 
axial SpAs, HLA-B27 alone is not diagnostic of SpAs, 
and, conversely, most features of peripheral SpA can 
occur in HLA-B27-negative patients. 
 
 
Juvenile Idiopathic Arthritis (JIA) 
The present accepted definition of juvenile idiopathic 
arthritis (JIA) is chronic arthritis persisting for more 
than 6 weeks in children below 16 years of age, 
without any apparent etiology. It is the most frequent 
joint disease of childhood, with an annual incidence of 




JIA is characterized by a variable pattern of articular 
involvement and systemic symptoms, and thus it has 
been classified in several subtypes.
49
 JIA, as most 
autoimmune   diseases,  is  a   multifactorial   condition  
caused by the interaction between environment and a 
genetic background. There is wide evidence that HLA 




In an attempt to better define HLA associations with 
the different subsets of JIA, together with colleagues 
from the University Hospital in Pavia, we carried out a 
meta-analysis
51
 according to a protocol published in the 
PROSPERO International Prospective Register of 
Systematic Reviews 
(http://www.crd.york.ac.uk/PROSPERO) with 
registration number: CRD42017073065. We started out 
by evaluating 565 papers, nine of which met our 
eligibility criteria. The main findings of our study can 
be summarized as follows: 
1) HLA-DRB1*08 is a strong factor predisposing to 
JIA, both for oligo-articular and poly-articular 
forms (Odds Ratio 6.0); 
2) HLA-DRB1*01 and HLA-DRB1*04 may be 
involved in the genetic predisposition of RF+ forms 
of JIA; 
3) HLA-DRB1*11 was confirmed to be predisposing 
to oligo-articular JIA;  
4) HLA-DRB1*04 was confirmed to have a role in 
systemic JIA. Importantly, RF positivity seems to 
select the JIA clinical subset with the strongest 
immunogenetic similarities with adult RA. 
From the practical point of view, HLA typing is of 
interest only for research purposes, to the extent that it 
could shed some light on etiology and pathogenesis of 
the different JIA forms. However, at present, HLA 






Figure 2. The role of HLA typing in Rheumatic diseases 
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CONCLUSION 
The rheumatic disorders discussed in this review, i.e. 
RA, SpA and JIA, are, to a variable degree, associated 
with HLA. Figure 2 aims at summarizing the HLA 
allelic groups and alleles found to be correlated to the 
different disease subtypes. 
In this paper, we attempted to illustrate the present-day 
practical use of HLA typing in disease diagnosis and 
prognosis. It is interesting to note that some authors 
have a less restrictive view on the practical role of 
HLA typing; Roudier and colleagues
52
 prescribe HLA-
A, -B, -C, -DRB1 typing to all patients for whom a 
rheumatic disease is suspected. According to the 
authors, this provides a diagnostic orientation in 
patients with recent onset disease, before the 
development of typical clinical features, especially in 
those individuals negative for autoantibodies. This 
approach is hindered by the elevated cost of HLA 
typing, and could be more widely adopted should 
typing costs decrease significantly. In our personal 
experience, HLA typing has proven useful in 
supporting diagnosis in some clinically unclear 
situations and in the early stages of the disease. 
Future prospects of HLA studies in rheumatic diseases 
will benefit from new insights on the non-coding 
region variation, on the consequences of regulatory 
variation on HLA expression and its possible impact on 
disease.
53
 Moreover, an emerging role of Natural Killer 
cells and HLA-C might shed new light on the 
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